{"id":"romosozumab-followed-by-denosumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Hypocalcemia"},{"rate":null,"effect":"Arthralgia"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Osteonecrosis of the jaw (rare)"}]},"_chembl":{"chemblId":"CHEMBL1237023","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Romosozumab is a sclerostin inhibitor that promotes osteoblast activity and new bone formation while transiently reducing bone resorption. Denosumab is a RANKL inhibitor that potently suppresses osteoclast differentiation and function, reducing bone turnover. This sequential approach leverages the anabolic phase of romosozumab followed by sustained anti-resorptive effects of denosumab to maximize bone mineral density gains and fracture risk reduction.","oneSentence":"Romosozumab stimulates bone formation via Wnt signaling inhibition, followed by Denosumab which blocks osteoclast-mediated bone resorption, providing sequential anabolic then anti-catabolic therapy for osteoporosis.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:05:36.355Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Osteoporosis in postmenopausal women at high risk of fracture"}]},"trialDetails":[{"nctId":"NCT04800367","phase":"PHASE2","title":"Romosozumab/Denosumab Study for Premenopausal IOP","status":"ACTIVE_NOT_RECRUITING","sponsor":"Columbia University","startDate":"2021-03-12","conditions":"Premenopausal Idiopathic Osteoporosis","enrollment":30},{"nctId":"NCT06811363","phase":"","title":"Contribution of Bone to Urine Citrate","status":"ENROLLING_BY_INVITATION","sponsor":"University of Texas Southwestern Medical Center","startDate":"2026-02-28","conditions":"Osteoporosis","enrollment":25},{"nctId":"NCT06938152","phase":"PHASE4","title":"Effects of Cycle Therapy vs Sequential Therapy With Romosozumab and Denosumab in Postmenopausal Osteoporosis Patients","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-04-08","conditions":"Osteoporosis, Osteoporosis Postmenopausal","enrollment":70},{"nctId":"NCT05101018","phase":"PHASE4","title":"Treatment With Romosozumab Versus Denosumab to Improve Bone Mineral Density and Architecture in Subacute SCI","status":"ACTIVE_NOT_RECRUITING","sponsor":"James J. Peters Veterans Affairs Medical Center","startDate":"2021-11-01","conditions":"Osteoporosis, Spinal Cord Injuries","enrollment":40},{"nctId":"NCT04232657","phase":"PHASE2","title":"Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI","status":"ACTIVE_NOT_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2021-03-01","conditions":"Spinal Cord Injury (=3 Years), Sublesional Bone Loss Secondary to SCI","enrollment":36},{"nctId":"NCT01575834","phase":"PHASE3","title":"Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis","status":"COMPLETED","sponsor":"Amgen","startDate":"2012-03-15","conditions":"Postmenopausal Osteoporosis","enrollment":7180}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":122,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sequential therapy group"],"phase":"marketed","status":"active","brandName":"Romosozumab followed by Denosumab","genericName":"Romosozumab followed by Denosumab","companyName":"National Taiwan University Hospital","companyId":"national-taiwan-university-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Romosozumab stimulates bone formation via Wnt signaling inhibition, followed by Denosumab which blocks osteoclast-mediated bone resorption, providing sequential anabolic then anti-catabolic therapy for osteoporosis. Used for Osteoporosis in postmenopausal women at high risk of fracture.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}